An Ebola signature

The team has successfully defined a “formula” capable of predicting the efficacy and safety of new Ebola virus vaccines.

By studying the plasma from 115 Genevan volunteers who took part in a clinical trial of a candidate virus in 2015, researchers observed that the concentration of five inflammation markers was sufficient to understand the gist of the immune response to the virus.

This promising formula is a practical and easy-to-use equation: addition of the concentrations of five substances whose activity is controlled by the monocytes – a category of white blood cells known for fighting the Ebola virus in the human body.

Find an actor

BioAlps Networking Day 201829.11.2018

L'événement aura lieu au SICHH le 29 novembre 2018 au blueFACTORY à Fribourg

AMAL Therapeutics raises 33.2 million dollars

The Geneva-based startup just announced the completion of its Series B financing round, raising in total CHF 33.2...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn